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Background: Hepatocellular carcinoma (HCC) is the second leading cause of cancer
death worldwide and hepatitis B is one of the commonest causes. T regulatory cells
(Tregs) are strong immunomodulators and are likely to play a major role in HCC devel-
opment. HBV infection is reported to induce expansion of Tregs. We investigated the
CD4+CD25+CD127−veFoxP3+Tregs in HBV-related HCC as compared to non-HBV-HCC.
Patients and Methods: Whole blood immunophenotyping was analyzed by multicolor
flow cytometry in patients with HBV-related HCC (HBV-HCC, n=17), non-HBV-HCC (n=22;
NASH=16, alcohol-related=6), and chronic hepatitis B infection (CHBV; n=10).Tregs func-
tionality was checked by in vitro suppression assays using CD4+ CD25+ CD127low Tregs.
Levels of serum alpha-fetoprotein (AFP), expression of FoxP3, IL-10, PD1,TGF-β, and Notch
in Tregs, and liver explants were analyzed by flow cytometry, immunohistochemistry, and
quantitative RT-PCR.
Results: CD4+CD25+hi and Foxp3 expression in CD4+CD25+hiCD127low was signifi-
cantly increased (P = 0.04, P =0.007) in HBVHCC compared to non-HBVHCC and CHBV
patients. HBVHCC also showed high IL-10 and TGF-β secreting CD4 + CD25 + hiTregs. The
PD1 expression in CD4+CD25+hi was significantly decreased in the HBVHCC than
non-HBVHCC. In HBVHCC, AFP levels were significantly high (median 941, range 2–
727940) than non-HBVHCC (median 13.5, range 2–18,900). In HBVHCC, patients with high
AFP (range; 3982–727940 ng/ml) showed positive correlation with Foxp3 expression in
CD4+CD25+hi CD127low (r =0.857, P =0.014). Reduced PD1 expression in HBVHCC also
had negative correlation with FOXP3 in CD4+CD25+hi CD127low (r =−0.78, P =0.04).
However, AFP levels in non-HBVHCC showed negative correlation with (R =−0.67,
P =0.005) with CD4+CD25+hi Tregs.
Conclusion: Our results demonstrate that CD4+ CD25+hi Tregs from HBVHCC patients
have decreased expression of PD1, resulting in higher IL-10 andTGF-β secretion. Increased
suppressive ability of Tregs in HBV-related HCC confers increased anti-tumor suppres-
sive response than in non-HBV-HCC. Modulation of Tregs and PD1 may serve as useful
therapeutic targets.
Keywords: T regulatory cells, hepatitis B virus, hepatocellular carcinoma, transforming growth factor-β,
alpha-fetoprotein
INTRODUCTION
Hepatocellular carcinoma (HCC) is the second most common
cancer worldwide and its incidence in Asia is on a rise (1). The most
important causes leading to HCC are HBV and HCV infections,
autoimmune hepatitis, heavy alcohol consumption, aflatoxin B1,
obesity, iron overload, age, and gender (males are more suscepti-
ble than females). However, hepatitis B virus-related chronic liver
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TGF-β,
transforming growth factor-β; Tregs, T regulatory cells.
disease is the most important risk factor for development of HCC.
Importantly 50–60% of HCC in Asia is associated with chronic
HBV infection (2–4).
Clearance of hepatitis B infection is T cell dependent and dur-
ing acute infection, T cell responses are vigorous, polyclonal, and
multi-specific. However, in chronically infected patients, T cell
responses are relatively weak and narrowly focused. Apparently,
CD8+ T cells are the key cellular effectors mediating HBV clear-
ance from the liver and CD4+ T cells help them to clear the virus.
Regulatory T cells (Tregs) play an important role in regulating
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the immune system by suppressing self-reactive CD4 and CD8 T
cells (5–7).
Naturally occurring and inducible Tregs exert their suppressive
effects either via cell to cell contact by membrane-bound molecules
or through contact-independent manner mainly by release of IL-
10 and TGF-β cytokines (8). TGF-β and IL-10 are responsible for
the suppression of anti-tumor immune responses and therefore
lead to successful tumor escape (9). During chronic inflamma-
tion, induction of Tregs happens through activation of Notch and
Wnt signaling (10–12).
T regulatory cells (Tregs) in periphery as well as in tumor area
express more of Foxp3 and specifically inhibit CD8 T cell activ-
ity, thereby blocking virus-specific immune responses and leading
to viral persistence (13–18). During chronic hepatitis B infection,
frequency of circulating Tregs increases, which are able to mod-
ulate virus and tumor antigen-specific immune responses (19,
20). However, increase of Tregs is inversely proportional to HBV
DNA titers. In the later stages of infection, during fibrosis and cir-
rhosis, abundant TGF-β favors the differentiation and expansion
of Tregs. In cirrhotic patients, Treg frequency increases in both
peripheral blood and liver compared to non-cirrhotic patients.
Therefore, Tregs-mediated immunosuppression contributes to
ideal microenvironment for oncogenic transformations (21). In
addition, Tregs with increased FOXP3 and CTLA4 expression in
tumor microenvironment show marked elevation in the ratio of
TGF-β/IL-17 (22).
However, the precise mechanism of regulatory T cells
in HBV-induced HCC has not been compared with non-
HBV-related HCC. Therefore, we undertook to compare the
CD4+CD25+CD127low regulatory T cells and their regulation
by TGF-B, IL-10, and PD1 in patients with HBV induced HCC vs.
non-HBV-related HCC.
PATIENTS AND METHODS
PATIENTS
Hepatocellular carcinoma (HCC) patients were diagnosed based
on classical radiological features of arterial enhancement and
venous washout with raised alfa-feto protein, and if needed,
histological confirmation on biopsy or surgical specimens
was done.
Hepatocellular carcinoma patients were divided into two
categories: hepatitis B virus-infected (HBV-HCC; n= 17) and
non-HBV-HCC (n= 22; cryptogenic= 16, NASH= 4, ALD= 2).
Treatment naïve chronic hepatitis B patients (CHB, n= 10)
HBsAg with raised ALT, HBsAg+ for more than 6 months and
with histological evidence of chronic hepatitis.
Exclusion criteria
The patients with daily alcohol consumption in last 1 month, dia-
betes, severe systemic illness, pregnancy, co-infection with HIV,
or other hepatic viruses, or receiving immunosuppressive therapy
for other associated illness were excluded. The study was approved
by the Institutional Ethics Committee and informed consent was
obtained from each patient.
Whole blood was collected in k3 EDTA vials. Tissues from
HBV-HCC and non-HBV-HCC patients, undergoing liver trans-
plant/resection were collected and stored in liquid nitrogen. Tissue
piece to be used for RNA isolation was stored in RNA later
at−20°C.
FLOW-CYTOMETRIC ANALYSIS
Whole blood was permeabilized and fixed using cytofix/cytoperm
(BD Pharmingen, San Jose, CA, USA) according to manufacturer’s
protocol followed by staining for 20 min at room temperature
in the dark with cocktail of antibodies including anti-CD4-
APC, anti-CD25-FITC, anti-FOXP3-PE, anti-PD1-PeCy7, anti-
IL10-APC, anti-CD127-APC, anti-CD8PeCy5, anti-NOTCH1 PE,
and anti TGF-β APC (BD Pharmingen, CA, USA). After staining,
RBCs were lysed using BD FACS lysing solution (BD Pharmingen,
San Jose, CA, USA) as per manufacturer’s instructions.
Anti-Notch1 PE antibody (clone mN1A) was procured from
eBiosciences, CA, USA; mN1A antibody reacts with the intra-
cellular domain of human Notch1. The mN1A antibody has a
low affinity for the full-length (unprocessed or heterodimeric
cell surface) forms of Notch1. Therefore, Notch1 expression was
considered intracellular not surface expression.
More than 50,000 cells were acquired for flow-cytometric analy-
ses on BD FACS Caliber and the results were analyzed using the
TreeStar Flow-Jo software version 8.8.7.
ISOLATION OF PBMCs
Ten to fifteen milliliters of blood samples were centrifuged at
800 g for plasma separation. After removing plasma, pooled blood
was diluted in cold PBS and PBMCs were isolated by Ficoll–
Hypaque density gradient centrifugation. PBMCs were suspended
in RPMI1640 medium supplemented 10% fetal bovine serum
(FBS) for further use. The viability of isolated cells was determined
by trypan blue exclusion staining.
CD4+CD25+CD127low T regulatory cell isolations
Ten to fifteen milliliters of whole blood was processed for isolation
of CD4+CD25+CD127low regulatory T cells using manufacturer’s
protocol (Stem cell technology, Vancouver, BC, Canada).
IN VITRO SUPPRESSION ASSAYS USING CFSE
Freshly isolated CD4+CD25+CD127low Tregs were used directly
to assess their functional suppressive capacity. CD4+CD25− cells
were stained with 500 nM CFSE and incubated for 12 min at
37°C. After incubation, cells were washed twice with pre-warmed
1640 RPMI culture medium. After counting, the cells are ready
for use. CD4+CD25+CD127low Treg cells from HBV-HCC and
non-HBV-HCC patients were co-cultured with CFSE labeled
CD4+CD25− cells from the same patient at ratios 1:10. CFSE
labeled CD4+CD25-CD127low cells without Treg cells were used
as control. Cells were stimulated by anti-CD3 (1µg/ml) and anti-
CD28 (1µg/ml) and cultured in RPMI 1640 medium (HiMedia)
supplemented with 10% FBS and 1 penstrep for 72 h at 37°C with
5% CO2. Proliferation of CD4+CD25−CD127low cells was deter-
mined by measuring CFSE dilution with flow-cytometric analyses
using BD FACS Calibur and the results were analyzed using the
TreeStar Flow-Jo software version 8.8.7.
Total RNA isolation
Extraction of total RNA was done from PBMCs, CD4+CD25high
CD127low Treg cells, CD4+CD25− cells, and resected liver tissues
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using MIRVana kit (Ambion,Austin, TX, USA). The concentration
of RNA was measured using Nanodrop ND-1000 (ThermoScien-
tific, USA). A total of 1–2µg of the RNA was used for cDNA
preparation using random hexamer primers.
QUANTITATIVE REAL-TIME PCR
qRT-PCR was performed for CD25, TGF-β, IL-10, PDL1, PDL2,
FOxP3, Notch, and wnt signaling molecules using SYBR Green
PCR Kit (Applied Biosystems, USA) and ABI PRISM 7700
Sequence Detector with ViiA 7 software (Applied Biosystems,
USA). The primers of all genes were designed using Primer 3 soft-
ware (Table 1). The gene expression level was normalized against
18S (control gene) RNA. Relative gene expression values expressed
as fold change were subsequently determined using the 2−∆∆CT
method.
IMMUNOHISTOCHEMICAL ANALYSIS
Immunohistochemistry staining was performed on 3µm sections
of paraffin-embedded resected liver tissue specimen for PD1,
CD25, FOXP3, PDL1, and TGF-β in HBV-HCC (n= 5) and
non-HBV-HCC (n= 5) patients.
Sections were stained with chromogen DAB (DAKO, Suyog
Diagnostics Pvt. Ltd., Mumbai, India) and counterstained with
hematoxylin. The condition for use of primary polyclonal antibod-
ies were optimized and PD1 (Santa Cruz Biotechnology) FoxP3,
PDL1, and TGF-β (Abcam, St Louis, MO, USA), were used at the
1:25 and 1:50 dilution, while CD25 antibody was ready to use anti-
body. Cellular localization, cytoplasmic, and nuclear positivity of
the respective protein expression was carefully observed.
STATISTICAL METHODS
All the data comparisons are expressed as mean± SD or median
with range. The continuous data were compared using one way
ANOVA or Kruskal–Wallis Test followed by post hoc compari-
son by Bonferroni method. Spearman’s correlation was used to
calculate correlation in between parameters and also with alpha-
fetoprotein (AFP) values. The significance is indicated with a P
value <0.05.
RESULTS
CLINICAL AND VIROLOGICAL CHARACTERISTICS OF SUBJECTS
The clinical and virological characteristics of 49 patients are
shown in Table 2. There were no significant differences in the
age and sex in all groups. However, AFP levels were high in HBV-
HCC (mean, 123077± 234626 vs. 1339± 4448 (Figure 1A) and
median 941, range, 2–7,279,40 ng/ml in HBV-HCC vs. median
13.5 range 2–18,900 ng/ml, P = 0.03 in non-HBV-HCC patients
(Table 2).
DECREASED TOTAL LYMPHOCYTES AND CD8+ T CELLS IN HBV-HCC
THAN NON-HBV-HCC PATIENTS
Flow-cytometric analysis in whole blood revealed that total lym-
phocytes were significantly lower in HBV-HCC compared to both
CHBV (P = 0.003 and P = 0.04, Figure 1B) and non-HBVHCC
patients. There was no significant difference in the frequen-
cies of CD4+ T cells in all three groups (Figure 1C). CD8+
Table 1 | Oligo sequences used in the study for quantitative RT-PCR.
S. no. Gene Oligo sequence
1 IL-10 5′-CCGCCTCAGCCTCCCAAAGT-3′
5′-CCCTAACCTCATTCCCCAACCAC-3′
2 TGF-β 5′-GAGGCGCCCGGGTTATGCTGGTTG-3′
5′-CGCAAGGACCTCGGCTGGAAGTGG-3′
3 CD25 5′-TGGACACACAAGGTGCAA-3′
5′-TGTGACCTCCATCCCTTCTC-3′
4 FoxP3 5′-CACCTGGCTGGGAAAATGG-3′
5′-GGAGCCCTTGTCGGATGAT-3′
5 Wnt 3a 5′-CGCGAGTCGGCCTTCGTTCA-3′
5′-AGGCGGCCCCTTATGATGCG-3′
6 Cyclin D1 5′-CTCCATCCAGGGATTCTTCA-3′
5′-TTTTTGGAGCTTCTGGCTGT-3′
7 β-catenin 5′-GACAGCAATCAGCTGGCCTGGT-3′
5′-ACCACTCCCACCCTACCAACCA-3′
8 Notch 1 5′-CGGGTCCACCAGTTTGAATG-3′
5′-GTTGTATTGGTTCGGCACCAT-3′
9 Notch 2 5′-GTGCAGGAATTGGAAAGTTGGA-3′
5′-GGCCGCTTCAGAGGAAAAG-3′
10 Notch 3 5′-GCCATCTCCCTTTGGGAACT-3′
5′-CCACATTTACAGGGACATAAAGGA-3′
11 Notch 4 5′-CCAAGAAATGCCCATAAACCAA-3′
5′-GCCTTTTAATGGGTAATCATTTTTG-3′
12 Jagged 1 5′-CCAGGTCTTACTACGGAGCACATT-3′
5′-CGCAAGCGATGTAGATTGAATATT-3′
13 Hey 2 5′-TACTTTGACGCACACGCTCT-3′
5′-CGCAAGTGCTGAGATGAGAC-3′
14 Hes1 5′-GGACATTCTGGAAATGACAGTGAA-3′
5′AGCGCAGCCGTCATCTG-3′
T cells were also significantly lower in HBV-HCC compared to
both CHBV and non-HBVHCC patients (P = 0.003 and P = 0.04,
Figure 1D).
HIGHER REGULATORY T CELLS IN HBV-HCC PATIENTS
Intra-cytoplasmic expression of FoxP3 is key regulatory fac-
tor for Tregs, therefore, we have assessed Foxp3 expression in
CD4+ CD127low CD25+hi in HBV-HCC and non-HBV-HCC
patients. Frequencies of CD4+ CD127low CD25+hi cells were
significantly high (P = 0.05) in HBV-HCC patients than non-
HBVHCC patients. Further, key regulatory expression of Foxp3 in
CD4+CD127lowCD25+hi was also significantly high in HBV-HCC
compared to non-HBV-HCC (P = 0.002; Figures 2A,B).
Foxp3 expression in CD4+ CD127low CD25+hi was signif-
icantly correlated with both low (<1000, r = 0.857, P = 0.014)
and high (>1000, r = 0.914, P = 0.000) AFP values in HBV-HCC
patients, which was not correlated in non-HBV-HCC patients
(Tables S1–S3 in Supplementary Material).
There was no difference in frequencies of CD8+CD25+ hi in
HBV-HCC than non-HBVHCC patients (P =NS, Figures S1A,B
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Table 2 | Clinical and virological characteristics of subjects recruited in the study.
Parameters Non-HBV-HCC HBV-HCC CHBV P value
*Non-HBV-HCC vs. HBV-HCC
**HBV-HCC vs. CHBV
Age (years), mean±SD 59±8.5 54±10 36±13.6 NS
Sex (M:F) 17 : 5 14 : 3 9 : 1 NS
AST (IU/ml), median (range) 97.5 (71–763) 109.5 (73–229) 70.5 (41–966) NS
ALT (IU/ml), median (range) 73 (51–402) 71 (51–229) 72 (46–872) NS
HBsAg Non-reactive Reactive Reactive –
HBeAg – – Reactive –
AFP (ng/ml), median (range) 13.5 (2.4–18,900) 943.5 (2.24–575736.6) 38.2 (2.45–120.6) 0.047*, 0.045**
HBV DNA (IU/ml), median (range) – 1645 (77.6–7.52×106) 20.6×106 (10–1.10×108) 0.04**
*P value: Non-HBV-HCC vs. HBV-HCC; **P value: HBV-HCC vs. CHBV.
FIGURE 1 | (A) Alpha-fetoprotein level is a predictive marker of HCC and its
values are high in HBVHCC than non-HBV-HCC. (B–D) Representative
flow-cytometric dot plots and scatter plots showing differential frequencies of
total lymphocytes, CD4, and CD8T cells. Total lymphocyte counts and CD8+T
cells were decreased in HBV-HCC than non-HBV-HCC and CHBV.There was no
significant difference in CD4+T cell counts in between all the three groups.
Frontiers in Immunology | T Cell Biology February 2015 | Volume 6 | Article 49 | 4
Sharma et al. Anti-tumor suppressive Tregs in HBV-HCC
FIGURE 2 | (A) CD4+CD25+CD127low Tregs were analyzed using CD25 and
CD127 markers on CD4+ gated population of T cells. Representative
flow-cytometric dot plots and scatter plot showing the frequencies of
CD4+CD25+CD127low Tregs in all three groups. (B) Scatter plot shows
increased expression of FoXP3 positive CD4+CD25+CD127low Tregs in
HBV-HCC than non-HBVHCC (P =0.002).
FIGURE 3 |Tregs from HBV-HCC are functionally more suppressive. T
conventional cells from HBV-HCC and non-HBV-HCC patients were CFSE
labeled and cultured for 72 h with patient matched Tregs (1:10 for Tregs: Tcon)
to assess CFSE dilution. Tregs from HBV-HCC showed significantly high
suppression of Tcon after 72 h of co-culture (right panel) as compared to Tregs
from non-HBV-HCC.
in Supplementary Material) but in comparison to CHBV
patients, CD8+ Tregs frequencies were slightly higher in
HBV-HCC patients (P = 0.05). However, Foxp3 expression
in CD8+CD25+hi was significantly high in HBV-HCC than
non-HBV-HCC (P = 0.04) and CHBV patients (P = 0.002, Figure
S1B in Supplementary Material).
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FIGURE 4 | (A,B) Representative flow-cytometric dot plots showing the
expression of IL-10 and TGF-β in Tregs in three patient groups. Scatter plot
shows that both IL-10 and TGF-β were expressed significantly more in Tregs
of HBV-HCC patients than both non-HBV-HCC and CHBV. (C) qRT-PCR
analysis confirmed the overexpression of TGF-β in HBV-HCC than
non-HBV-HCC. (D) Immunohistochemistry analysis also confirmed the
over expression of TGF-β in HBV-HCC than non-HBV-HCC liver tissues. 40×
magnification was used.
CD4+CD25+CD127LOW TREGS IN HBV-HCC PATIENTS ARE
FUNCTIONALLY MORE SUPPRESSIVE THAN NON-HBV-HCC PATIENTS
In order to assess the ability of regulatory T cells to suppress
other antigen-specific or non-specific T cells, in vitro suppres-
sion assay was set up to analyze the suppressive ability of
CD4+CD25+CD127lo cells (Tregs). In this assay, T cells from
HBV-HCC and non-HBVHCC patients were CFSE labeled (Tcon)
and co-cultured with and without Tregs at a concentration of 1:10
(Tregs: Tcon) for 72 h to assess CFSE dilution. In both groups,
Tcon alone were proliferated enough in 72 h indicated by CFSE
dilution of 97.5 and 91.1%. However, after 72 h of co-culture
with Tregs from HBV-HCC and non-HBV-HCC patients, Tcon
proliferated less and there was only 22.3% dilution of CFSE as
compared to 88.2% in non-HBVHCC patients. This suggests that
Tregs from HBV-HCC inhibited the proliferation of Tcon more
than non-HBVHCC patients (Figure 3).
T regulatory cells exert their immunosuppressive activity
through production of cytokines like IL-10 and TGF-β or
through Notch-mediated cell to cell contact. We observed by
flow cytometry, that intracellular secretion of IL-10 and TGF-β
FIGURE 5 | Immunohistochemical analysis showed increased
expression of CD25 and FoxP3 in HBV-HCC patients (A,B) than
non-HBV-HCC patients (C,D), Magnification: 40×.
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FIGURE 6 | (A–C) Representative flow-cytometric dot plots and scatter plot showing increased expression of PD1 on CD4+CD25+Tregs of non-HBV-HCC
patients than HBV-HCC patients. (D) Immunohistochemistry on paraffin-embedded sections confirming the increased expression of PD1 and PDL1 (c,d) in
non-HBV-HCC than HBV-HCC (a,b) patients. Magnification: 40×.
was higher in HBV-HCC Tregs than non-HBVHCC (IL-10;
P = 0.01; and TGF-β; P = 0.04, Figures 4B,C). QRT-PCR and
immune histochemical analysis showed the increased expression
of TGF-β in HBV-HCC Tregs than non-HBVHCC Tregs (P = 0.01,
Figures 4C,D). Secretion of IL-10 was also increased in HBV-
HCC Tregs compared to CHBV patients also (IL-10; P = 0.02;
Figure 4A).
Expansion of Tregs is driven by activation of Notch signal-
ing also. Therefore, we have assessed Notch expression by qRT-
PCR as well as by intracellular staining of Notch1 in HBV-HCC
Tregs. Flow-cytometric analysis revealed that intracellular expres-
sion of Notch1 was significantly increased in HBV-HCC than
non-HBVHCC Tregs (P = 0.048; Figure S2 in Supplementary
Material).
The expression of CD25 and FoxP3 was further analyzed by
immunohistochemistry in paraffin-embedded sections of HBV-
HCC and non-HBVHCC cases. Both CD25 and FoxP3 were
expressed more in HBV-HCC than non-HBV-HCC (Figure 5).
DECREASED PROGRAMED CELL DEATH MOLECULE PD1 IN HBV-HCC
TREGS
To check the differentiation status of Tregs and also as inhibit-
ing marker, we have analyzed the expression of PD1 in
CD4+CD25+hi Tregs, PD1 showed lower expression in Tregs of
HBV-HCC than non-HBV-HCC compared to HBV-HCC patients
(Figure 6).
PD1 expression is negatively correlated in patients with low AFP
values (r =−0.778, P = 0.039) in HBVHCC patients; however, no
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such correlation was made in non-HBV-HCC patients (Table S1
in Supplementary Material).
Immunohistochemistry also showed a decreased expression of
PD1 in HBV-HCC (+) patients than non-HBVHCC patients (+
+ +) (Figure 6); however, there was no significant difference
in the expression of PDL1 (ligand for PD1) in HBV-HCC than
non-HBVHCC patients.
DISCUSSION
Chronic HBV infection plus long-term recurrent immune-
mediated liver damage contributes to the development of
HCC. Tregs-mediated suppression potentially hinders an effec-
tive immune response, which is crucial for elimination of tumors
and infection (23). However, how Treg impairs the host immune
to favor tumor growth is not clearly understood in various
etiology-based HCC.
In this study, we observed that HBV-HCC patients have
an increased percentage of FoxP3+CD4+CD25+CD127low T
cells phenotypes. AFP, which is a HCC marker often associ-
ated with tumor size, was also significantly high in HBV-HCC
patients than non-HBVHCC patients. Furthermore, high AFP
levels in HBV-HCC patients showed significantly positive corre-
lation with Foxp3 expression in CD4+CD25+hiCD127low cells
(r = 0.857, P = 0.014), while in non-HBVHCC cases no such
correlation could be made. In other study also, proportion of
CD4+CD25highFOXP3+Tregs was significantly higher in patients
with high serum AFP levels (24). However, AFP correlation
with Tregs is controversial. In one of the study, poor correla-
tion between CD4+CD25+ Tregs and tumor marker AFP was
reported (25).
In addition, our study showed inverse relation with high Tregs
and decreased CD8+ effector T cells in HBV-HCC than non-
HBV-HCC patients. Further, CFSE assay showed that Tregs from
HBV-HCC patients could significantly reduce the proliferation of
effector T cells in comparison to those isolated from non-HBV-
HCC patients. In fact, earlier studies have also proposed that both
circulatory and intra-tumoral Tregs may promote HCC progres-
sion by decreasing and impairing the effector functions of CD8+
T cells (23, 26).
TGF-β and IL-10 are major cytokines through which the
Tregs exert their suppressive function (27). Importantly, TGF-β
produced by iTregs can induce other naive CD4+CD25− cells to
become similar suppressor cells (28) whereas IL-10 enhances the
production of TGF-β and also controls the ability of target cells to
respond to TGF-β (29). We found that both TGF-β and IL-10 were
secreted more by Tregs from HBV-HCC than non-HBV-HCC and
thus would be more suppressive.
In chronic disease stage, PD1 pathway normally gets activated
and is involved in promoting tolerance and preventing tissue dam-
age (30). In our study, PD1 expression was less in Tregs in HBV-
HCC than non-HBV-HCC patients. In non-HBVHCC, increased
expression of PD1 on Tregs indicates that Tregs can be exhausted
and their capability of suppression can be compromised.
In this study, HBV-HCC patients showed an increased expres-
sion of Notch 1 on Tregs from HBV-HCC compared to those
from non-HBVHCC patients. Notch signaling helps in devel-
opment and functioning of Tregs (10). In vitro studies have
shown that blockade of Notch1 signaling inhibits Treg suppressor
function (12).
In conclusion, Tregs in HBV-HCC patients are not only high
in number but are also functionally more suppressive and pos-
itively correlate with AFP, and their mechanism of suppression
through TGF-β. AFP value more than 100 thereby conferring
an increased anti-tumor suppressive response as compared to
non-HBV-HCC patients. Further, therapeutic interventions can
consider Tregs: AFP correlation to characterize the HBV-HCC
patients.
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